Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Significant Accounting Policies (Tables)

v3.23.1
Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Schedule of property, plant and equipment
    %     Mainly
%		  
             
Laboratory equipment   10     10  
             
Computers, office furniture and equipment   6 - 33     33  

 
Schedule of major customer data as a percentage of total revenues
    Year ended December 31,  
    2022     2021     2020  
                   
Cipher Pharmaceuticals (Canada)     11 %     12 %     20 %
Chong Kun Dang Pharmaceuticals Corp. (South Korea)     25 %     24 %     45 %
Gebro Holding GmbH (Austria)     18 %     23 %     35 %
Ewopharma AG (Switzerland)     46 %     41 %    
-
  
                         
 Total     100 %     100 %     100 %

 
schedule of outstanding share options and warrants
    Year ended December 31,  
    2022     2021     2020  
                   
Options     27,002,200       18,422,700       11,923,400  
Warrants     375,197,640       377,947,640       228,192,286  
                         
Total     402,199,840       396,370,340       240,115,686